AMA Honors Moul For 'US TOO' Support

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

BETHESDA, Md--Judd W. Moul, MD, director of the Center for Prostate Disease Research (CPDR), established by Congress in 1991, has been awarded the American Medical Association's Young Physicians Section Community Service Award for his role in helping to establish prostate cancer patient support groups within the military health-care system.

BETHESDA, Md--Judd W. Moul, MD, director of the Center for ProstateDisease Research (CPDR), established by Congress in 1991, hasbeen awarded the American Medical Association's Young PhysiciansSection Community Service Award for his role in helping to establishprostate cancer patient support groups within the military health-caresystem.

Dr. Moul, an Army physician and urologist, was instrumental inestablishing a charter chapter of US TOO, the prostate cancersupport group, at Walter Reed Army Medical Center in Washington,DC, in 1991. Since then, the chapter has become the largest prostatecancer support group in the United States. Dr. Moul is also anadvisor to the US TOO International, Inc. organization.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content